Type I collagen promotes tumor progression of integrin β1 positive gastric cancer through a BCL9L/β-catenin signaling pathway.
Animals
Apoptosis
/ drug effects
Cell Line, Tumor
Cell Proliferation
/ drug effects
Collagen Type I
/ pharmacology
DNA-Binding Proteins
/ metabolism
Extracellular Matrix
/ metabolism
Female
Gene Expression Regulation, Neoplastic
Humans
Integrin beta1
/ genetics
Mice
Mice, Inbred NOD
Mice, SCID
Signal Transduction
Stomach Neoplasms
/ genetics
Transcription Factors
/ metabolism
Xenograft Model Antitumor Assays
beta Catenin
/ metabolism
BCL9L
gastric cancer
integrin β1
type I collagen
β-catenin
Journal
Aging
ISSN: 1945-4589
Titre abrégé: Aging (Albany NY)
Pays: United States
ID NLM: 101508617
Informations de publication
Date de publication:
28 07 2021
28 07 2021
Historique:
received:
01
01
2021
accepted:
05
06
2021
pubmed:
29
7
2021
medline:
15
12
2021
entrez:
28
7
2021
Statut:
ppublish
Résumé
The mechanism of extracellular matrix induced tumor progression is poorly understood. Based on the TCGA database and clinical tumor tissues analysis, we observed abundant type I collagen expression in tumor tissues and poor overall survival in gastric patients with high integrin β1 (ITGB1) expression.
Identifiants
pubmed: 34319913
pii: 203355
doi: 10.18632/aging.203355
pmc: PMC8351671
doi:
Substances chimiques
BCL9L protein, human
0
CTNNB1 protein, human
0
Collagen Type I
0
DNA-Binding Proteins
0
Integrin beta1
0
Itgb1 protein, human
0
Transcription Factors
0
beta Catenin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
19064-19076Références
Am J Transl Res. 2016 Feb 15;8(2):922-31
pubmed: 27158379
J Clin Oncol. 2016 Oct 1;34(28):3451-9
pubmed: 27507882
Biomaterials. 2020 Oct;256:120217
pubmed: 32736172
J Clin Invest. 2012 Apr;122(4):1529-40
pubmed: 22378044
Cancer Res. 2011 Feb 1;71(3):1019-28
pubmed: 21148071
Oncogene. 2013 Jan 17;32(3):327-40
pubmed: 22349830
J Transl Med. 2019 Sep 14;17(1):309
pubmed: 31521169
J Hematol Oncol. 2013 May 13;6:35
pubmed: 23668363
J Endocrinol. 2011 May;209(2):139-51
pubmed: 21307119
Cancer Res. 2010 Aug 15;70(16):6619-28
pubmed: 20682801
Surgery. 2011 Aug;150(2):306-15
pubmed: 21719059
Tissue Cell. 2012 Feb;44(1):1-6
pubmed: 22071216
Lancet. 2016 Nov 26;388(10060):2654-2664
pubmed: 27156933
Biophys J. 2014 Dec 2;107(11):2546-58
pubmed: 25468334
Clin Exp Metastasis. 2013 Jun;30(5):569-78
pubmed: 23242739
Int J Gynecol Cancer. 2012 Oct;22(8):1316-24
pubmed: 23013730
Nat Med. 2014 Apr;20(4):332-3
pubmed: 24710372
Oncol Lett. 2016 Mar;11(3):2001-2008
pubmed: 26998113
Mol Biol Cell. 2012 Sep;23(17):3357-69
pubmed: 22809628
Cancer Res. 2013 Oct 15;73(20):6243-53
pubmed: 23872583
Chemother Res Pract. 2012;2012:283181
pubmed: 22567280
Cancer Res. 2017 Nov 1;77(21):5831-5845
pubmed: 28904065
Matrix Biol. 2017 Jan;57-58:213-243
pubmed: 27562932
Elife. 2017 Mar 15;6:
pubmed: 28296634
Nat Commun. 2019 Feb 13;10(1):723
pubmed: 30760720
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Adv Drug Deliv Rev. 2016 Feb 1;97:270-9
pubmed: 26485156
Sci Transl Med. 2012 Aug 22;4(148):148ra117
pubmed: 22914623
J Med Chem. 2012 Feb 9;55(3):1137-46
pubmed: 22196480
Biomaterials. 2012 Feb;33(5):1437-44
pubmed: 22078807
Front Oncol. 2015 Oct 20;5:224
pubmed: 26539408
Biomaterials. 2019 Feb;193:47-57
pubmed: 30554026
World J Gastroenterol. 2014 Feb 21;20(7):1635-49
pubmed: 24587643